Show simple item record

Article

dc.creatorCisneros Herreros, José Migueles
dc.creatorRosso Fernández, Claraes
dc.creatorRoca Oporto, Cristinaes
dc.creatorDe Pascale, Gennaroes
dc.creatorJiménez Jorge, Silviaes
dc.creatorFernández Hinojosa, Estebanes
dc.creatorGarnacho Montero, Josées
dc.date.accessioned2020-04-29T11:54:16Z
dc.date.available2020-04-29T11:54:16Z
dc.date.issued2019-11-28
dc.identifier.issn1364-8535es
dc.identifier.urihttps://hdl.handle.net/11441/95961
dc.description.abstractBackground: Colistin is recommended in the empirical treatment of ventilator-associated pneumonia (VAP) with a high prevalence of carbapenem-resistant gram-negative bacilli (CR-GNB). However, the efficacy and safety of colistin are not well defined. Methods: A multicenter prospective randomized trial conducted in 32 European centers compared the efficacy and safety of colistin (4.5 million unit loading dose followed by a maintenance dose of 3 million units every 8 h) versus meropenem (2 g every 8 h), both in combination with levofloxacin (500 mg every 12 h) for 7–14 days in patients with late VAP. Between May 2012 and October 2015, 232 patients were randomly assigned to the 2 treatment groups. The primary endpoint was mortality at 28 days after randomization in the microbiologically modified intention-to-treat (mMITT) population. Secondary outcomes included clinical and microbiological cure, renal function at the end of the treatment, and serious adverse events. The study was interrupted after the interim analysis due to excessive nephrotoxicity in the colistin group; therefore, the sample size was not achieved. Results: A total of 157 (67.7%) patients were included in the mMITT population, 36 of whom (22.9%) had VAP caused by CR-GNB. In the mMITT population, no significant difference in mortality between the colistin group (19/82, 23.2%) and the meropenem group (19/75, 25.3%) was observed, with a risk difference of − 2.16 (− 15.59 to 11.26, p = 0.377); the noninferiority of colistin was not demonstrated due to early termination and limited number of patients infected by carbapenem-resistant pathogens. Colistin plus levofloxacin increased the incidence of renal failure (40/120, 33.3%, versus 21/112, 18.8%; p = 0.012) and renal replacement therapy (11/120, 9.1%, versus 2/112, 1.8%; p = 0.015). Conclusions: This study did not demonstrate the noninferiority of colistin compared with meropenem, both combined with levofloxacin, in terms of efficacy in the empirical treatment of late VAP but demonstrated the greater nephrotoxicity of colistin. These findings do not support the empirical use of colistin for the treatment of late VAP due to early termination.es
dc.description.sponsorshipSeventh Framework Program of the European Commission. Magic Bullet: 278232.es
dc.formatapplication/pdfes
dc.format.extent13es
dc.language.isoenges
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectColistines
dc.subjectVentilator-associated pneumoniaes
dc.subjectMultidrug-resistant bacteriaes
dc.subjectCarbapenem-resistant gram-negative bacillies
dc.titleColistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial.es
dc.typeinfo:eu-repo/semantics/articlees
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicina.es
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Citología e Histología Normal y Patológ.es
dc.identifier.doi10.1186/s13054-019-2627-yes
dc.journaltitleCritical Carees
dc.publication.volumen23es
dc.publication.issue1es

FilesSizeFormatViewDescription
Colistin versus meropenem.pdf1.155MbIcon   [PDF] View/Open  

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as: Attribution-NonCommercial-NoDerivatives 4.0 Internacional